Nalaganje...
Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α(4)β(7) integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot stud...
Shranjeno v:
| izdano v: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5578211/ https://ncbi.nlm.nih.gov/pubmed/28829369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18081827 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|